DLL3 and neuroendocrine carcinoma: DLL3 is frequently expressed in neuroendocrine carcinomas (NEC), notably small-cell and large-cell variants, while being uncommon in well-differentiated GEP-NETs, supporting DLL3 as a therapeutic target primarily in NEC rather than NET [85].